

CASE REPORT

Open Access



Major pathologic response to alectinib in *ALK*-rearranged adenocarcinoma of the lung

Naoko Imanishi¹, Kazue Yoneda¹, Akihiro Taira¹, Yoshinobu Ichiki¹, Naoko Sato², Masanori Hisaoka³ and Fumihiko Tanaka^{1*} 

Abstract

Background: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the *ALK* gene. Here, we present the first surgical case of *ALK*-rearranged lung adenocarcinoma with major pathological response in resected specimens after treatment with alectinib.

Case presentation: A 65-year-old female with clinical stage IIIA-N2 *ALK*-rearranged adenocarcinoma originating from the left lower lobe presented. Involvement of lower para-tracheal node was pathologically confirmed by endobronchial ultrasound-guided biopsy. Alectinib was prescribed, as the patient may not tolerate radiotherapy due to a mental illness. After 3 months' treatment with alectinib, a remarkable radiological and metabolic response was achieved. The patient did not tolerate further continuation of alectinib treatment, and surgery was performed without any morbidity. Only < 10% tumor cells were viable in all resected specimens, indicating major pathological response to alectinib.

Conclusions: Salvage surgery after alectinib treatment may be safe and effective for initially unresectable NSCLC harboring *ALK*-rearrangements.

Keywords: ALK, Alectinib, Pathologic response, Adenocarcinoma, Lung

Background

Non-small cell lung cancer (NSCLC) with rearrangement of the *anaplastic lymphoma kinase (ALK)* gene is a distinct subtype of lung cancer. Crizotinib, the first approved tyrosine kinase inhibitor (TKI) of ALK, provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced *ALK*-rearranged NSCLC [1]. Alectinib is a highly selective ALK-TKI and has showed superior efficacy in two randomized phase 3 studies comparing crizotinib with alectinib [2, 3]. Here, we report the first case of *ALK*-rearranged lung adenocarcinoma with major pathological response in resected specimens after treatment with alectinib, which may provide a pathological rationale for its greater clinical efficacy

for advanced patients and may warrant clinical trials of adjuvant treatment of alectinib for resectable *ALK*-rearranged NSCLC patients. In addition, salvage surgery after alectinib treatment for initially unresectable *ALK*-rearranged NSCLC patients may be feasible. This study was approved by the Ethics Committee of the University of Occupational and Environmental Health, Japan, and the written informed consent was taken from the patient.

Case presentation

A 65-year-old female with a mental illness (bipolar disorder) was referred to our institute for the treatment of *ALK*-rearranged lung adenocarcinoma originating from the left lower lobe. Chest computed tomography (CT) and positron emission tomography (PET) scan revealed enlargement of lower para-tracheal node with a moderate uptake of fluoro-deoxy-glucose (FDG) (Fig. 1), and endobronchial ultrasound-guided biopsy

* Correspondence: ftanaka@med.uoeh-u.ac.jp

¹Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health Japan, Kitakyusyu, Japan
Full list of author information is available at the end of the article




Fig. 1 Computed tomography and positron emission tomography before the treatment

provided pathological evidence of nodal involvement. Whole-body CT/PET scan and brain magnetic resonance imaging revealed no distant metastasis, and her lung adenocarcinoma was diagnosed with clinical stage IIIA-N2 disease.

Alectinib treatment was performed to the patient, as she did not tolerate radiotherapy due to the mental illness. After 3 months' treatment with alectinib, a remarkable radiological and metabolic response was achieved (Fig. 2). The patient did not tolerate further continuation of alectinib treatment, and

surgery was performed. We had continued alectinib treatment until the day before surgery. Complete resection was achieved with combined resection of left lower lobe and lingular segment with systematic nodal dissection, and postoperative course was uneventful. Pathological examination revealed that only <10% tumor cells were viable in all resected specimens, indicating major pathological response to alectinib (Fig. 3). The patient refused any additional treatment and is alive without any tumor recurrence at 5 months after surgery.




Fig. 2 Computed tomography and positron emission tomography after the treatment with alectinib




Fig. 3 Histological findings after the treatment with alectinib. (Left) No viable tumor cells are seen in most pathological sections cut from the primary tumor and lymph nodes. (Right) Only a small number of atypical cells were seen in some primary tumor sections (upper) and nodal sections (lower)

Discussion

ALK-TKIs usually provide good radiological and metabolic response in most *ALK*-rearranged NSCLC. However, pathological response to ALK-TKIs remains unknown because ALK-TKIs are indicated only for unresectable patients. In the English literature, only two cases showing pathologic response to an ALK-TKI have been reported [4, 5]. In both cases, good radiological and metabolic response was achieved with crizotinib treatment, but pathological specimens revealed only minimal response [4, 5]. In contrast, major pathologic response was achieved in the current case treated with alectinib. These results as well as superior clinical efficacy of alectinib over crizotinib in phase 3 studies [2, 3] may indicate a more potent anti-tumor activity of alectinib.

The major pathologic response achieved with alectinib may warrant clinical trials of alectinib in postoperative adjuvant treatment for resectable *ALK*-rearranged NSCLC patients. A variety of targeting agents such as an antibody against the vascular endothelial growth factor (VEGF) and TKIs of the epidermal growth factor receptor (EGFR) are now tested in clinical trials for resectable NSCLC patients, but these agents can cause unexpected bleeding or delayed wound healing which may lead to increased morbidity and mortality. In contrast, as observed in the present case, ALK-TKIs may not cause such fatal operative complications because ALK targeted by these agents may not express in normal tissues in the adult.

The standard care of treatment for clinical IIIA-N2 NSCLC is chemoradiation, but alectinib treatment was performed in the current case because the patient did not tolerate radiotherapy due to bipolar disorder. After

3 months' treatment of alectinib, the patient did not even tolerate further continuation of alectinib treatment, and salvage surgery was conducted. We planned to preform only the best supportive care, even when complete resection was not achieved or postoperative recurrence occurred. Fortunately, the postoperative course was uneventful, and the patient is alive without tumor recurrence at 5 months after surgery. The current case may indicate that salvage surgery after alectinib treatment for initially unresectable NSCLC patients is feasible.

Conclusions

We presented the first case of *ALK*-rearranged lung adenocarcinoma with major pathological response in resected specimens after treatment with alectinib. Salvage surgery after alectinib treatment may be safe and effective for NSCLC harboring *ALK*-rearrangements.

Abbreviations

ALK: Anaplastic lymphoma kinase; CT: Computed tomography; EGFR: Epidermal growth factor receptor; FDG: Fluoro-deoxy-glucose; NSCLC: Non-small cell lung cancer; PET: Positron emission tomography; TKI: Tyrosine kinase inhibitor; VEGF: Vascular endothelial growth factor

Funding

No specific funding was disclosed.

Authors' contributions

NI, AT, and YI performed the operation. KY performed the molecular analysis of specimens for gene alterations. NS and MH performed the pathological diagnosis. All authors designed and drafted the manuscript. FT designed and conducted the study and wrote the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the University of Occupational and Environmental Health, Japan. A written informed consent was obtained from the patient.

Competing interests

Fumihito Tanaka received lecture fees from Chugai Pharmaceutical Co. Ltd. The other authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health Japan, Kitakyusyu, Japan. ²Department of Pathology, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyusyu, Japan. ³Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyusyu, Japan.

Received: 13 January 2018 Accepted: 1 March 2018

Published online: 09 March 2018

References

1. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014;371:2167–77.
2. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. *Lancet*. 2017;390:29–39.
3. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med*. 2017;377:829–38.
4. Kaseda K, Watanabe K, Asakura K, Kazama A. Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case. *World J Surg Oncol*. 2015;13:74.
5. Dumont D, Do P, Lerouge D, Planchard G, Riffet M, Dubos-Arvis C, et al. Off-label use of crizotinib as a neoadjuvant treatment for a young patient when conventional chemotherapy gave no benefits in stage IIIA non-small cell lung cancer. *Am J Case Rep*. 2017;18:890–3.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com
